Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates

Diagnostic Microbiology and Infectious Disease

Volumn 49, Issue 1, 2004, Pages 63-65

  Jones, Ronald N ^a,b   Fritsche, Thomas R ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PEPTIDE DEFORMYLASE INHIBITOR;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; LISTERIA; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS BOVIS; STREPTOCOCCUS PNEUMONIAE;

AMIDOHYDROLASES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY;

EID: 2342654040     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2003.12.005     Document Type: Article

References (18)

1. Ackermann G., Rodloff A.C. Drugs of the 21st century: Telithromycin (HMR 3647): The first ketolide. J Antimicrob Chemother. 51:2003;497-511
2. Adams J.M. On the release of the formyl group from nascent protein. J Molec Biology. 33:1968;571-589
3. Anderegg TR, Biedenbach DJ, Jones RN, The Quality Control Working Group (2003). Quality control guidelines for MIC susceptibility testing of NVP PDF-713, a novel peptide deformylase inhibitors. Int J Antimic Agents 22, 84-86
4. Apfel C.M., Locher H., Evers S., Takacs B., Hubschwerlen C., Pirson W., Page M.G.P., Keck W. Peptide deformylase as an antimicrobial drug target: Target validation and resistance development. Antimicrob Agents Chemother. 45:2001;1058-1064
5. Canu A., Leclercq R. Overcoming bacterial resistance by dual target inhibition: The case of streptogramins. Curr Drug Targets Infect Disorders. 1:2001;215-225
6. Clements J.M., Beckett R.P., Brown A., Catlin G., Lobel M., Palan S., Thomas W., Whittaker M., Wood S., Salama S., Baker P.J., Rodgers H.F., Barynin V., Rice D.W., Hunter M.G. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother. 45:2001;563-570
7. Craig WA, Andes D (2002). In vivo pharmacodynamics of BB-89698, a deformylase inhibitor. In: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, abstr. #F-355, pp. 206. American Society for Microbiology, Chicago, IL
8. Hackbarth C.J., Chen D.Z., Kewis J.G., Clark K., Mangold J.B., Cramer J.A., Margolis P.S., Wang W., Koehn J., Wu C., Lopez S., Withers G. III, Gu H., Dunn E., Kulathila R., Pan S.H., Porter W.L., Jacobs J., Trias J., Patel D.V., Weidmann B., White R.J., Yuan Z. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother. 46:2002;2752-2764
9. Jones R.N., Rhomberg P.R. Comparative spectrum and activity of NVP PDF-386 (VRC4887) a new peptide deformylase inhibitor. J Antimicrob Chemother. 51:2003;157-161
10. Livermore D.M. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis. 36:(Suppl 1):2003;S11-S23
11. Margolis P.S., Hackbarth C.J., Young D.C., Wang W., Chen D., Yan Z., White R., Trias J. Peptide deformylase in Staphylococcus aureus: Resistance to inhibition is mediated by mutations in the formyl transferase gene. Antimicrob Agents Chemother. 44:2000;1825-1831
12. Margolis P., Hackbarth C., Lopez S., Maniar M., Wang W., Yuan Z., White R., Trias J. Resistance to Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob Agents Chemother. 45:2001;2432-2435
13. Mutnick A.H., Enne V., Jones R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother. 37:2003;769-774
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6. 2003;NCCLS, Wayne, PA
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing M100-S13. 2003;NCCLS, Wayne, PA
16. Roblin P.M., Hammerschlag M.R. In vitro activity of a new antibiotic, NVP PDF386 (VRC4887), against Chlamydia pneumoniae. Antimicrob Agents Chemother. 47:2003;1447-1448
17. Thorarensen A., Douglase M.R. Jr, Rhorer D.C., Vosters A.F., Yem A.W., Marshall V.D., Lynn J.C., Bohanon M.J., Tomich P.K., Zurenko G.E., Sweeney M.T., Jensen R.M., Nielsen J.W., Seest E.P., Dolak L.A. Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg Med Chem Let. 11:2001;1355-1358
18. Waller A.S., Clements J.M. Novel approaches to antimicrobial therapy: Peptide deformylase. Curr Opin Drug Discovery Dev. 5:2002;785-792